3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Melanoma
116
Carcinoma, Non-Small-Cell Lung
101
Carcinoma, Renal Cell
67
Colorectal Neoplasms
46
Neoplasm Metastasis
40
Squamous Cell Carcinoma of Head and Neck
38
Carcinoma, Hepatocellular
38
Neoplasms
35
Lung Neoplasms
34
Stomach Neoplasms
33
Urinary Bladder Neoplasms
22
Hodgkin Disease
20
Carcinoma, Transitional Cell
20
Brain Neoplasms
20
Pancreatic Neoplasms
18
Ovarian Neoplasms
18
Prostatic Neoplasms
16
Head and Neck Neoplasms
16
Colonic Neoplasms
16
Skin Neoplasms
15
Sarcoma
14
Glioblastoma
14
Adenocarcinoma Of Esophagus
14
Triple Negative Breast Neoplasms
13
Carcinoma, Merkel Cell
13
Small Cell Lung Carcinoma
12
Rectal Neoplasms
12
Esophageal Neoplasms
12
Breast Neoplasms
12
Uveal Melanoma
11
Interventions
olaparib
4
Pluvicto
4
Abiraterone Acetate
3
testosterone 17 beta-cypionate
2
radium Ra 223 dichloride
2
enzalutamide
2
darolutamide
2
Prednisone
2
Prednisolone
2
Docetaxel
2
Androgen Antagonists
2
sipuleucel-T
1
lactitol
1
fludarabine phosphate
1
fludarabine
1
fluciclovine F-18
1
enfortumab vedotin
1
cabozantinib
1
cabazitaxel
1
alovudine
1
abiraterone
1
Standard of Care
1
Radium-223
1
PSMA-617
1
Nivolumab
1
Gonadotropin-Releasing Hormone
1
Cyclophosphamide
1
Bortezomib
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Castration-resistant Prostate Cancer
×
Nivolumab
×
1 year
×
Clear all
NCT04109729
2026-06-01
Rad2Nivo
University of Utah
Phase 1
Active not recruiting
39 enrolled